Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

Keyphrases

• Parkinson's Disease 100%
• Motor Complications 100%
• Dopamine Receptor 100%
• Scientific Rationale 100%
• Levodopa 50%
• Basal Ganglia 33%
• Patients with Parkinson's Disease 33%
• Pulse Stimulation 33%
• Disability 16%
• Clinical Benefit 16%
• Dopamine 16%
• Monkey 16%
• Normal Brain 16%
• Levodopa Therapy 16%
• Molecular Changes 16%
• Dopamine Neurons 16%
• Short-acting 16%
• Oral Formulation 16%
• Continuous Infusion 16%
• Striatal Dopamine 16%
• Ganglion Neurons 16%
• Neuronal Firing 16%
• Common Source 16%
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 16%
• Continuous Dopaminergic Stimulation 16%
• Continuous Delivery 16%
• State Standards 16%

Neuroscience

• L-DOPA 100%
• Dopaminergic 100%
• Dopamine Receptor 100%
• Treatment of Parkinson's Disease 100%
• Parkinson's Disease 50%
• Basal Ganglia 50%
• Tetrahydropyridine 25%

Medicine and Dentistry

• Dopamine Receptor 100%
• Levodopa 100%
• Treatment of Parkinson's Disease 100%
• Parkinson's Disease 50%
• Basal Ganglia 50%
• Continuous Infusion 25%
• 1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine 25%
• Oral 25%